pentobarbital will lower the extent or influence of meloxicam by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
pentobarbital will reduce the extent or outcome of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
Warning with use through surgical procedures or techniques in young children youthful than three yr or in pregnant Ladies through their 3rd trimester
pentobarbital will lower the level or impact of oliceridine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe. If coadministration using a CYP3A4 inducer is critical, contemplate escalating oliceridine dose till stable drug consequences are obtained; observe for indications of opioid withdrawal.
pentobarbital decreases results of hemin by pharmacodynamic antagonism. Use Warning/Keep an eye on. Drugs that boost delta-aminolevulinic acid synthetase may perhaps decrease hemin result.
pentobarbital will lower the level or influence of conivaptan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will minimize the extent or result of triamcinolone acetonide injectable suspension by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
This drug may interfere Together with the absorption of orally administered griseofulvin, lowering its blood levels; results of blood stage reduction not known; preferable to stay away from concomitant administration of these medicines
pentobarbital will lessen the level or effect of nilotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital improves toxicity of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. CYP3A4 inducers may possibly raise the metabolism of ifosfamide to its Energetic alkylating metabolites.
Check Closely (one)pentobarbital will enhance the amount or outcome of clopidogrel by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
Clients stabilized on corticosteroid therapy may require dosage changes if barbiturates are included to or withdrawn from their dosage program resulting from induction of hepatic microsomal enzymes by barbiturates
fentanyl transdermal and pentobarbital the two enhance sedation. Keep away from or Use Alternate Drug. Restrict use to people for whom alternative therapy selections are insufficient
Keep away from; coadministration with CYP3A inducers may perhaps result in decreased plasma concentrations of elvitegravir and/or simply a concomitantly administered protease inhibitor and lead Nembutal to loss of therapeutic impact and also to attainable resistance